Loading stock data…
MIRM
$107.54+1.73 (+1.64%)
Market OpenUpdated 2:20 PM EDT
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Mirum Pharmaceuticals, Inc. in the Healthcare sector is trading at $107.54. The stock is currently near its 52-week high of $110.48, remaining 33.6% above its 200-day moving average. Technical signals show overbought RSI of 71 and bullish MACD crossover, explaining why MIRM maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 71) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$107.54
Potential Upside
5%
Whystock Fair Value$112.92
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$138.18+28.5%
Range$112.00 – $175.00
Fundamentals
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.69B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.52
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-18.61%
Volume
Today's trading volume
442,281
Recent News
How The Mirum Pharmaceuticals (MIRM) Story Is Evolving With New Analyst Targets And Trial Milestones
Mirum Pharmaceuticals is back in focus as one updated fair value estimate shifts from US$106.60 to about US$129.73, reflecting a modeled target level that is roughly 22% higher. That change lines up with a flurry of recent Street research, where several firms have revisited their models, reset price targets into the US$120s and US$130 range, and highlighted both the opportunities and execution pressures tied to Livmarli and the broader bile acid portfolio. As you read on, you will see how...
The $1 Billion-Plus Opportunity That Sent Mirum Pharma Catapulting To A Record
Shares of Mirum Pharmaceuticals rocketed to an all-time high Monday on positive results for its experimental liver disease treatment.
Why This Biotech ETF — The IBD Stock Of The Day — Just Reentered Its Buy Zone
The SPDR S&P Biotech ETF, often referred to simply as the XBI, is Monday's IBD Stock Of The Day. Shares just reentered a buy zone.
Mirum Pharmaceuticals Says Volixibat Phase IIb VISTAS Hits Endpoint, Cuts PSC Itch vs Placebo
Mirum Pharmaceuticals (NASDAQ:MIRM) said its Phase IIb VISTAS study of volixibat in patients with primary sclerosing cholangitis (PSC) met its primary endpoint, showing a statistically significant reduction in cholestatic pruritus compared with placebo, according to executives on the company’s busin
Mirum's Volixibat Meets Phase 2b Study Goal, Shows Significant Itch Reduction in PSC
Mirum Pharmaceuticals (MIRM) said Monday that its investigational drug volixibat met the primary end